Increase of soluble FcγRIIIa derived from natural killer cells and macrophages in plasma from patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 30, Issue 9, 2003, Pages 1911-1917

  Masuda, Midori ^a   Morimoto, Tadanobu ^a   De Haas, Masja ^b   Nishimura, Noriko ^a   Nakamoto, Kyoko ^a   Okuda, Kazuyuki ^a   Komiyama, Yutaka ^a   Ogawa, Ryokei ^a   Takahashi, Hakuo ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

CD16 rheumatoid arthritis; Fc receptors; Macrophages; Natural killer cells

Indexed keywords

CD16 ANTIGEN; FC GAMMA RIII RECEPTOR; FC GAMMA RIIIA RECEPTOR; FC RECEPTOR; GLYCOSYLPHOSPHATIDYLINOSITOL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; SOLUBLE FC GAMMA RIIIA RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; ELECTROPHORETIC MOBILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LANSBURY INDEX; MACROPHAGE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; AGED; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HOSPITALIZATION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; OSTEOARTHRITIS; PROGNOSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SOLUBILITY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KILLER CELLS, NATURAL; MACROPHAGES; MALE; MIDDLE AGED; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, IGG; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 0041470202     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ravetch JV, Perussia BV. Alternative membrane forms of FcγRIII (CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989;170:481-97.
2. Edberg JC, Barinsky M, Redecha PB, Salmon JE, Kimberly RP. FcγRIII expressed on cultured monocytes is a N-glycosylated transmembrane protein distinct from FcγRIII expressed on natural killer cells. J Immunol 1990;144:4729-34.
3. de Haas M, Kleijer M, Minchinton RM, Roos D, von dem Borne AE. Soluble FcγRIIIa is present in plasma and is derived from natural killer cells. J Immunol 1994;152:900-7.
4. Huizinga TWJ, van der Schoot CE, Jost C, et al. The PI-linked receptor FcRIII is released on stimulation of neutrophils. Nature 1988;333:667-9.
5. Ory PA, Clark MR, Kwoh EE, Clarkson SB, Goldstein IM. Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils. J Clin Invest 1989;84:1688-91.
6. Huizinga TWJ, Kleijer M, Tetteroo PA, Roos D, von dem Borne AE. Biallelic neutrophil NA-antigen system is associated with a polymorphism on the phospho-inositol-linked Fcγ receptor III (CD16). Blood 1990;75:213-7.
7. de Haas M, Kleijer M, Roos D, von dem Borne AE. Characterization of MAbs of the CD16 cluster and six newly generation CD16 MAbs. In: Schlossmann SF, Boumsell L, Gilks W, et al. editors. Leukocyte typing V. Oxford: Oxford University Press; 1995:811-7.
8. Harrison D, Phillips JH, Lanier LL. Involvement of a metalloprotease in spontaneous and phorbol ester-induced release of natural killer cell-associated FcγRIII (CD16-II). J Immunol 1991;147:3459-65.
9. Levy PC, Utell MJ, Fleit HB, Roberts NJ, Ryan DH, Looney RJ. Characterization of human alveolar macrophages Fc Receptor III: A transmembrane glycoprotein that is shed under in vitro culture conditions. Am J Resp Cell Mol Biol 1991;5:307-14.
10. Huizinga TWJ, de Haas M, van Oers MH, et al. The plasma concentration of soluble FcγRIII is related to production of neutrophils. Br J Haematol 1994;87:459-63.
11. Homburg CHE, de Haas M, von dem Borne AE, Verhoeven AJ, Reutelingsperger CPM, Roos D. Human neutrophils lose their surface FcγRIII and acquire annexin V binding sites during apoptosis in vitro. Blood 1995;85:532-40.
12. Middelhoven PJ, van Buul JD, Hordijk PL, Roos D. Different proteolytic mechanisms involved in FcγRIIIb shedding from human neutrophils. Clin Exp Immunol 2001;125:169-75.
13. Brinckerhoff CE. Joint destruction in arthritis: metalloproteases in the spotlight. Arthritis Rheum 1991;34:1073-5.
14. Ostensen M, Forre O. Modulation of human natural killer cell function by cytokines and rheumatic disease. Scand J Rheumatol 1988;76 Suppl:183-8.
15. Hendrich C, Kuipers JG, Kolanus W, Hammer M, Schmidt RE. Activation of CD16+ effector cells by rheumatoid factor complex: Role of natural killer cells in rheumatoid arthritis. Arthritis Rheum 1991;34:423-31.
16. Tak PP, Kummer JA, Hack CE, et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994;37:1735-43.
17. Bhatia A, Blades S, Cambridge G, Edwards JCW. Differential distribution of FcγRIIIA in normal human tissues and colocalisation with DAF and fibrillin-1. Immunology 1998;94:56-63.
18. Sautes C, Teillaud C, Mazieres N, et al. Soluble Fcγ receptors: Detection in biological fluids and production of a murine recombinant sFcγR biologically active in vitro and in vivo. Immunobiology 1992;185:207-21.
19. Galon J, Moldovan I, Galinha A, et al. Identification of the cleavage site of plasma soluble Fc receptor type III (CD16). Eur J Immunol 1998;28:2101-7.
20. Koene HR, de Haas M, Kleijer M, Roos D, von dem Borne AE. NA-phenotype-dependent differences in neutrophil FcγRIIIb expression cause differences in plasma levels of soluble FcγRIII. Br J Haematol 1996;93:235-41.
21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Lansbury J. Methods for evaluating rheumatoid arthritis. In: Hollander JL, editor. Arthritis and allied conditions. 7th ed. Philadelphia: Lea and Febiger; 1966:269-91.
23. Koene HR, Kleijer M, Roos D, de Haas M, von dem Borne AE. FcγRIIIB gene duplication: Evidence for presence and expression of three distinct FcγRIIIB genes in NA(1+,2+)SH(+) individuals. Blood 1998;91:673-9.
24. Furuya D, Yagihashi A, Yajima T, et al. An immuno-polymerase chain reaction assay for human interleukin-18. J Immunol Methods 2000;238:173-80.
25. Masuda M, Nakamura S. Murakami T, Komiyama Y, Takahashi H. Association of tissue factor with a γ-chain homodimer of the IgE receptor type I in cultured human monocytes. Eur J Immunol 1996;26:2529-32.
26. Watanabe Y, Yamaguchi R, Egawa S, Shimamori Y, Fujimoto Y, Matsuno H. Activation of progelatinase B in synovial fluids of patients with rheumatoid arthritis, with reference to stromelysin-1 and tissue inhibitor of matrix metalloproteinase-1. Clin Exp Rheumatol 1999;17:401-6.
27. Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Tsukimura T. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 2001;28:22-8.
28. Ribbens C, Martin y Porras M, Franchimont N, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002;61:161-6.
29. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001;88:10-5.
30. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.